Leaf4Life taps Phase Advance to forecast KizaVie Phase 3 trials

Leaf4Life has partnered with Phase Advance to model Phase 3 outcomes for KizaVie, its hypoxia-targeting drug, across 16 therapeutic indications. The collaboration is meant to help the company prioritize development, support fundraising and potentially speed the path to regulatory review.

Why it matters: - Leaf4Life is using in silico forecasting to narrow where KizaVie may have the strongest clinical and commercial case. - The collaboration could help Leaf4Life allocate resources to the indications with the highest expected return and reduce uncertainty before human trials expand. - Leaf4Life is also raising funding for future human trials, and the Phase Advance projections are expected to support investor discussions.

What happened: - Leaf4Life announced a strategic collaboration with Phase Advance to forecast Phase 3 clinical trials for KizaVie. - The modeling work covers 16 therapeutic indications, including a basket trial for seven cancers. - The announcement said the goal is to compress the time needed for KizaVie to seek regulatory approval. - The companies did not disclose financial terms.

The details: - KizaVie is described as a drug designed to address oxygen-starved, or hypoxic, tissues. - Leaf4Life said KizaVie’s potential spans lung diseases, sepsis, tumors, trauma, shock, mitigation of GLP-1 adverse events and longevity. - Phase Advance will use a non-linear mathematics model and AI-powered platform to simulate virtual patients. - The simulations are intended to estimate optimal dose, dose schedules, duration of therapy, efficacy, biomarker selection and disease-stage timing. - Each trial is designed to model thousands of virtual patients and vary genetic background to reflect different patient populations. - Phase Advance said its approach has demonstrated 99.94% forecasting accuracy when measured against 29,111 patients in prospective clinical trials conducted months to years after the predictions. - Leaf4Life said KizaVie is a novel therapeutic class with no prior data available to train the model. - Phase Advance said its models are disease-agnostic and do not use large-language models.

Between the lines: - The partnership reflects growing interest in computer-generated trial design as biotech companies look for faster, cheaper ways to prioritize programs before late-stage spending. - KizaVie’s broad list of possible uses suggests Leaf4Life is still determining where the therapy may ultimately fit best, which makes predictive modeling especially valuable. - The emphasis on a basket trial for multiple cancers suggests Leaf4Life is exploring whether one mechanism could support several oncology paths at once. - Both companies framed the work as a way to reduce risk, but the real test will be whether the predictions translate into human trial results.

What's next: - Leaf4Life plans to move KizaVie toward clinical trials. - Phase Advance’s projections are expected to help determine which indications get priority. - Leaf4Life expects to use the modeling results in future fundraising. - The companies said the collaboration is aimed at guiding development decisions before broader clinical work begins.

The bottom line: - Leaf4Life is betting that advanced trial simulation can help turn KizaVie’s broad promise into a more focused drug-development strategy.